Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics.

Correll, Christoph U; Sliwa, Jennifer Kern; Najarian, Dean M; Saklad, Stephen R

Correll, Christoph U; Sliwa, Jennifer Kern; Najarian, Dean M; Saklad, Stephen R.

Afiliação

Correll CU; Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York.
Sliwa JK; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York.
Najarian DM; Janssen Scientific Affairs LLC, Titusville, New Jersey.
Saklad SR; Janssen Scientific Affairs LLC, Titusville, New Jersey.

CNS Spectr ; 24(4): 354-370, 2019 Aug.

Article em En | MEDLINE | ID: mdl-30587268

Palavras-chave

Antipsychotic; breakthrough symptoms; long-acting injectable; management strategy; schizophrenia; symptomatic worsening

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article